Ninlaro (Ixazomib)

Ninlaro is formulated as a proteasome inhibitor (PI) used in conjunction with medications lenalidomide and dexamethasone to treat individuals with multiple myeloma (MM) who have previously been treated with at least one therapy.

Recommended Dosage: The recommended beginning dosage of Ninlaro capsule is 4 mg administered orally once weekly on Days 1st, 8th, & 15th of a 28-day treatment cycle. The recommended starting dose of the drug lenalidomide is 25 mg administered daily on Days 1st through 21st of a 28-day treatment cycle. The recommended starting dose of dexamethasone is 40 mg administered on Days 1st, 8th, 15th, and 22nd of a 28-day treatment cycle.

Ninlaro needs to be taken at least 60 minutes before or at least 120 minutes after food. Capsules should be swallowed whole with water. Crushing, chewing, or opening the capsule is not recommended. In case of puking after taking a dose of Ninlaro, do not repeat the dose.

• Monitor platelet counts monthly throughout treatment with Ninlaro capsules. Perform more frequent monitoring during the initial 3 cycles. Thrombocytopenia may occur and need to be managed with the help of dose modifications as well as platelet transfusions.
• Cases, sometimes maybe fatal, of thrombotic microangiopathy, including hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP) may occur in all those who are on treatment with Ninlaro. Assess for signs and symptoms of HUS/TTP. If the diagnosis is confirmed, stop treatment and evaluate.
• Drug-induced hepatocellular injury, liver injury, hepatic steatosis, hepatitis cholestatic, and hepatotoxicity may occur in those treated with Ixazomib. Hepatic enzymes must be monitored regularly and adjust Ixazomib dosing for Grade 3/4 symptoms.
• Ninlaro 4 mg, 3 mg, or 2.3 mg capsules can cause fetal harm if administered during pregnancy on behalf of the mechanism of action and outcome in animal studies. Males with female partners of reproductive age should use relevant contraception during treatment and for 90 days after the final dose.

What documents are required to import NINLARO to India?

NINLARO (ixazomib) capsules can be imported by patients or government hospitals on the name of the patients only. 

The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patients ID Proof (issued by the government of India)

How does the order be confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from Doctor
• Import permit if applicable

Is NINLARO available in India?

NINLARO (ixazomib capsules) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input

• On availability of Ninlaro in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
• Medicine Price.
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
• Ensuring 100% transparency.

NINLARO can be made available to patients, doctors, and hospitals in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can help facilitate the supply of NINLARO (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Ninlaro price in India. 

We take to guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network is able to source the NINLARO (Cancer Treatment Medicines) from across the globe and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Ninlaro®?

Ixazomib is a Generic Name for the trade name drug Ninlaro®.

What is the Manufacturer’s Name of Ninlaro®?

Ninlaro® is manufactured by Takeda Pharmaceuticals Inc.

Is Ninlaro® approved by the FDA?

Yes, Ninlaro® is approved by the FDA. Date of first/initial approval: November 20, 2015.

Where can I get Ninlaro® at the best price in India?

To get the best Ninlaro Capsules price in India, kindly get in touch with Indian Pharma Network (a WHO GDP & ISO 9001:2008 certified company). For Ninlaro®, a valid medical prescription is required from a treating physician.

What is the dosage and form of Ninlaro® supplied?

Ninlaro® is supplied in Capsules: 4 mg, 3 mg, and 2.3 mg for oral administration. 

What are the most common side effects of Ninlaro®? 

The most common side effects of Ninlaro® are diarrhea, thrombocytopenia, neutropenia, constipation, peripheral edema, peripheral neuropathy, vomiting, nausea, rash, and bronchitis. 

How much does Ninlaro® cost in India?

The cost of Ninlaro in India can vary. In order to procure this medicinal product authentically, you can Call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

What are the storage conditions of Ninlaro®?

Store the capsules of Ninlaro at room temperature not above 30°C (86°F). Avoid freezing. Store them in their original packaging until immediately before use.

Is it safe to buy Ninlaro® online from India?

Yes, one can buy Ninlaro from India at the best price from the Indian Pharma Network (IPN) if Ninlaro is not registered or is unavailable in the respective country. We can facilitate the Import of Ninlaro through legal channels.